← SynDRA
GANAXOLONE
SynDRA canonical compound SYN0025580 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
| Primary target(s) | GABRA1 | GABRA2 | GABRA3 | GABRA4 | GABRA5 | GABRA6 |
| Mechanism of action | GABA receptor modulator |
All known targets
- GABRA1
- GABRA2
- GABRA3
- GABRA4
- GABRA5
- GABRA6
- GABRB1
- GABRG2
Mechanisms of action (all sources)
Drug classes
- GABA Agents
- GABA Modulators
- Neurosteroids
- Neurotransmitter Agents
- GABA A Receptor Positive Modulators
- Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator
ATC classes
Cross-references
Synonyms
- ztalmy
- GNX
- CCD 1042
- Ganaxolona
- Ztalmy
- CCD-1042
- CCD1042
- DEA NO. 2401
- Ganaxolone [USAN]
- Ganaxolone (USAN/INN)
- (3alpha,5alpha)-3-Hydroxy-3-methylpregnan-20-one
- 1-[(3R,5S,10S,13S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone
- 1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone
- 3alpha-Hydroxy-3-methyl-5alpha-pregnan-20-one
- 3alpha-Hydroxy-3beta-methyl-5alpha-pregnan-20-one
- Pregnan-20-one, 3-hydroxy-3-methyl-, (3alpha,5alpha)-
- ganaxolona
- DTXCID4026503
- ganaxolonum
- RefChem:57127
- C22H36O2
- NCGC00165802-02
- CAS-38398-32-2
- Ganaxolone [USAN:INN]
- UNII-98WI44OHIQ
- Ganaxolone, solid
- Pregnan-20-one, 3-hydroxy-3-methyl-, (3a,5a)-
- Ztalmy (TN)
- GANAXOLONE [MI]
- GANAXOLONE [INN]
- GANAXOLONE [WHO-DD]
- SCHEMBL144522
- GTPL11942
- CHEBI:177658
- PGTVWKLGGCQMBR-FLBATMFCSA-N
- HMS3261K19
- Tox21_112264
- Tox21_500379
Reported adverse events
- Pyrexia
- Sedation
- Somnolence
- Bronchitis
- Gait disturbance
- Influenza
- Nasal congestion
- Upper respiratory tract infection
- Seasonal allergy
Look up GANAXOLONE in the interactive SynDRA portal →